Advertisement
Table 1 Summary or selection criteria
| Category | Criteria |
|---|---|
| Population(s) | Individuals with dementia and BPSD living in the community, long term care, or in specialized longer stay settings |
| Intervention | All anticonvulsants for BPSD including valproic acid, gabapentin, pregabalin, carbamazepine, phenytoin, topiramate, levetiracetam, zonisamide, oxcarbazepine, lamotrigine, and phenobarbital. Benzodiazepines excluded |
| Control | Placebo, no intervention, or other active treatments including both non-pharmacologic or pharmacologic treatments |
| Outcomes | Primary outcomes: We will consider studies that use validated measures of BPSD such as |
| 1. Neuropsychiatric Inventory [19]. | |
| 2. Cohen-Mansfield Agitation Inventory [20] | |
| 3. Brief Psychiatric Rating Scale [21] | |
| 4. Clinical Global Impression Scale | |
| Secondary outcomes: | |
| 1. Caregiver burden and quality of life | |
| 2. Placement in long term care facility from home. | |
| 3. Serious adverse effects | |
| 4. Treatment discontinuation due to serious adverse effects | |
| Study design | Randomized control trials and crossover trials. |
| Timing | Any duration of follow-up longer than 2 weeks. |
